Personalized, tumor ‐informed, circulating tumor DNA assay for detecting minimal residual disease in non‐small cell lung cancer patients receiving curative treatments

ConclusionOur real-world data indicate that longitudinal, personalized, tumor-informed ctDNA monitoring is a valuable tool in patients with NSCLC receiving curative treatment to identify patients at high risk for recurrence.

Source: Thoracic Cancer - April 2, 2024 Category: Cancer & Oncology Authors: Youjin Oh, Sung Mi Yoon, Jeeyeon Lee, Joo Hee Park, Soowon Lee, Timothy Hong, Liam Il ‐young Chung, Sumedha Sudhaman, Timothy Riddell, Charuta C. Palsuledesai, Michael Krainock, Minetta C. Liu, Young Kwang Chae Tags: ORIGINAL ARTICLE Source Type: research